⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Women's Clinical Trials & CROs Market Forecast to More Than Double by 2036 as Precision Medicine Reshapes Trial Design
globenewswire.com
PFE
NVS
MRK
JNJ
Biond Biologics Appoints Giovanni Selvaggi, M.D., as Chief Medical Officer ("CMO")
prnewswire.com
BMY
NVS
GSK
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
KODK
RKDA
OTLK
UTHR
CLSD
AZN
BTE
CCNE
IONS
APLS
GYRO
NVS
GNTX
BLTE
JNJ
LCTX
ABBV
REGN
New Ebook Reveals Why Most Companies Are Failing the Employees Who Stay After Restructuring
globenewswire.com
ABT
AMST
GM
KMB
LMT
NVS
SCL
Next Generation Drug Conjugates Market Expected to Reach USD 42.55 Billion by 2035 | MarketsandMarkets™
globenewswire.com
AZN
NVS
ALNY
GILD
ABBV
IONS
SNY
Global Heart Hub finds women delay seeking heart care by continuing to put others first
prnewswire.com
AMGN
NVS
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
globenewswire.com
NVS
Antibody Partnering Surges into 2026: Q1 Deals Top $36 Billion as Bispecifics and Discovery Platforms Drive Competition
globenewswire.com
ABBV
LLY
MRK
NVS
PFE
SNY
GILD
BMY
JNJ
UCB
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
globenewswire.com
NVS
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN